ACR Appropriateness Criteria® nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliativ

GUIDELINE TITLE
ACR Appropriateness Criteria® nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.

BIBLIOGRAPHIC SOURCE(S)
Rosenzweig KE, Movsas B, Bradley J, Gewanter RM, Gopal RS, Komaki RU, Kong FM, Lee HK, Feins RH, Langer CJ, Expert Panel on Radiation Oncology-Lung. ACR Appropriateness Criteria® nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. [online publication]. Reston (VA): American College of Radiology (ACR); 2008. 14 p. [59 references]

GUIDELINE STATUS
This is the current release of the guideline.

The appropriateness criteria are reviewed annually and updated by the panels as needed, depending on introduction of new and highly significant scientific evidence.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

May 8, 2009 - Tarceva (erlotinib): OSI Pharmaceuticals, Inc., Genentech and the U.S. Food and Drug Administration (FDA) notified healthcare professionals of new safety information added to the WARNINGS AND PRECAUTIONS sections of the prescribing information for Tarceva. Gastrointestinal perforation (including fatalities), bullous, blistering and exfoliative skin conditions including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, in some cases fatal, and ocular disorders, including corneal perforation or ulceration have been reported during use of Tarceva.
September 23, 2008, Tarceva (erlotinib): OSI Pharmaceuticals and Genentech notified healthcare professionals that cases of hepatic failure and hepatorenal syndrome, including fatalities, have been reported during use of Tarceva, particularly in patients with baseline hepatic impairment. New information has been provided in the revised prescribing information, and other recommendations are included in the WARNINGS and DOSAGE AND ADMINISTRATION sections.

abrir aquí para acceder al documento NGC AHRQ completo:
ACR Appropriateness Criteria® nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliativ